<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-139109</identifier>
<setSpec>1576-9895</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">No disponible</dc:title>
<dc:description xml:lang="en">Lymphangioleiomyomatosis (LAM) is a rare disease that affects young females in their reproductive years. It is characterized by proliferation of abnormal smooth muscle-like cells (LAM cells) leading to progressive cystic destruction of the lung. Even though lung transplantation is considered the only treatment for severe LAM, some recent trials of sirolimus (mTOR inhibitor) showed that there was an improvement in lung function and a reduction in the size of renal angiomyolipomas. We report the case of a twenty years old woman with LAM associated to the tuberous sclerosis complex, who is being treated with sirolimus (AU)</dc:description>
<dc:creator>Alonso, T</dc:creator>
<dc:creator>García, E</dc:creator>
<dc:creator>Ancochea, J</dc:creator>
<dc:creator>Valenzuela, C</dc:creator>
<dc:creator>Gordillo, C</dc:creator>
<dc:creator>Girón, R</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La linfangioleiomiomatosis (LAM) es una enfermedad rara que se caracteriza por la proliferación anormal de células musculares lisas atípicas (células LAM) que condicionan la destrucción del parénquima pulmonar con formación de quistes. A pesar de que el trasplante pulmonar se considera la única opción terapéutica cuando la enfermedad progresa, ensayos clínicos recientes muestran que el tratamiento con sirolimus, fármaco inhibidor de mTOR (mammalian target of rapamycin), puede tener un efecto beneficioso sobre la función pulmonar y la reducción del tamaño de los angiomiolipomas renales que se asocian a la LAM. Presentamos el caso de una mujer de 20 años, diagnosticada de linfangioleiomiomatosis asociada a esclerosis tuberosa, en tratamiento con sirolimus (AU)</dc:description>
<dc:source>Rev. patol. respir;18(1): 30-32, ene.-mar. 2015. ilus</dc:source>
<dc:identifier>ibc-139109</dc:identifier>
<dc:title xml:lang="es">Sirolimus, una opción terapéutica en la linfangioleiomiomatosis</dc:title>
<dc:subject>^d2511^s22011</dc:subject>
<dc:subject>^d2511^s22053</dc:subject>
<dc:subject>^d2511^s22010</dc:subject>
<dc:subject>^d14190^s22024</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d14190^s22056</dc:subject>
<dc:subject>^d14190^s22045</dc:subject>
<dc:subject>^d3577^s22044</dc:subject>
<dc:subject>^d3577^s22012</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d3577^s22024</dc:subject>
<dc:subject>^d33809</dc:subject>
<dc:subject>^d3577^s22036</dc:subject>
<dc:subject>^d14804^s22053</dc:subject>
<dc:subject>^d14190^s22039</dc:subject>
<dc:subject>^d33809^s22000</dc:subject>
<dc:subject>^d33809^s22044</dc:subject>
<dc:subject>^d33809^s22055</dc:subject>
<dc:subject>^d14804^s22012</dc:subject>
<dc:subject>^d14804^s22033</dc:subject>
<dc:subject>^d14804^s22044</dc:subject>
<dc:subject>^d2511^s29165</dc:subject>
<dc:type>article</dc:type>
<dc:date>201503</dc:date>
</metadata>
</record>
</ibecs-document>
